David Kavanagh heads the National Renal Complement Therapeutics Centre (http://www.atypicalhus.co.uk/) . The NRCTC is a combined clinical, diagnostic and treatment centre for the complement mediated diseases: atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy. All patients in England treated with Eculizumab for these diseases are managed through the NRCTC. His research group investigates complement in renal and retinal diseases and is fully integrated with the NRCTC to provide rapid translational benefits to patients. He moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis. He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award. Additionally he runs a glomerulonephritis and vasculitis clinic at Freeman hospital. He is chairman of the aHUS rare disease working group and an executive committee member of Complement UK.Specialties: Atypical Haemolytic Uraemic Syndrome, Complement-related renal disease, Age-related macular degeneration (AMD), Complement biology, Translational Medicine, Retinal Vasculopathy with Cerebral Leucodystrophy (RVCL), Glomerulonephritis and Vasculitis.Follow us on Twitter at @renalresearchUK